Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD)

Journal of Clinical Pharmacology

Volumn 50, Issue 7, 2010, Pages 835-841

  Radin, Allen ^a   Marbury, Thomas ^b   Osgood, Greg ^a   Belomestnov, Pavel ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

Author keywords

IL 1 antagonist; Pharmacokinetics; Renal disease; Rilonacept

Indexed keywords

CRYOPYRIN; NEUTRALIZING ANTIBODY; RILONACEPT;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOINFLAMMATORY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEMATOLOGICAL PROCEDURES; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ALGORITHMS; ANTIBODIES, BLOCKING; AREA UNDER CURVE; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; RENAL DIALYSIS;

EID: 77953773942     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009351882     Document Type: Article

References (9)

1. Hoffman HM Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther. 2009 ; 9: 1-13.
2. Dinarello CA Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. Immunity. 2004 ; 20: 243-246.
3. Hoffman HM, Throne ML, AMar NJ, et al. Efficacy and safety of rilonacept (IL-1 trap) in cryopyrin-associated periodic syndromes (CAPS): results from two sequential placebo-controlled studies. Arthritis Rheum. 2008 ; 58: 2443-2452.
4. ARCALYST (rilonacept) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals ; February 2008.
5. Lovell DJ, Giannini EH, Kimura Y., et al. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2007 ; 56 (suppl): S514.
6. Terkeltaub R., Schumacher HR, Sundy J., et al. Placebo-controlled pilot study of rilonacept (IL-1 Trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Presented at: 2007 Annual Scientific Meeting of the American College of Rheumatology ; November 6-11, 2007 ; Boston.
7. Gabriel R. Morbidity and mortality of long-term haemodialysis: a review. J R Soc Med. 1984 ; 77: 595-601.
8. Don BR, Spin G., Nestorov I., Hutmacher M., Rose A., Kaysen G. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005 ; 57: 1407-1414.
9. Yang BB, Baughman S., Sullivan JT Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003 ; 74: 85-94.